ADMA Biologics, Inc.
ADMA
$8.41
$0.536.73%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 509.86M | 510.17M | 488.56M | 474.17M | 459.38M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 509.86M | 510.17M | 488.56M | 474.17M | 459.38M |
| Cost of Revenue | 197.45M | 217.41M | 221.28M | 222.86M | 217.84M |
| Gross Profit | 312.42M | 292.77M | 267.28M | 251.32M | 241.54M |
| SG&A Expenses | 98.86M | 96.42M | 96.37M | 92.91M | 87.09M |
| Depreciation & Amortization | 176.00K | 146.00K | 120.00K | 110.00K | 220.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 303.01M | 318.73M | 321.55M | 318.53M | 307.34M |
| Operating Income | 206.86M | 191.44M | 167.01M | 155.64M | 152.04M |
| Income Before Tax | 206.33M | 182.66M | 155.78M | 145.01M | 140.76M |
| Income Tax Expenses | 40.98M | 35.73M | -53.67M | -63.92M | -66.01M |
| Earnings from Continuing Operations | 165.35 | 146.93 | 209.45 | 208.93 | 206.77 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 165.35M | 146.93M | 209.45M | 208.93M | 206.77M |
| EBIT | 206.86M | 191.44M | 167.01M | 155.64M | 152.04M |
| EBITDA | 214.82M | 199.54M | 175.01M | 163.55M | 159.94M |
| EPS Basic | 0.69 | 0.62 | 0.88 | 0.88 | 0.88 |
| Normalized Basic EPS | 0.53 | 0.49 | 0.42 | 0.39 | 0.38 |
| EPS Diluted | 0.68 | 0.60 | 0.82 | 0.82 | 0.81 |
| Normalized Diluted EPS | 0.52 | 0.47 | 0.41 | 0.37 | 0.36 |
| Average Basic Shares Outstanding | 954.14M | 955.84M | 954.30M | 950.27M | 941.20M |
| Average Diluted Shares Outstanding | 977.08M | 981.80M | 983.85M | 983.99M | 977.55M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |